Zobrazeno 1 - 10
of 191
pro vyhledávání: '"E. E. Vokes"'
Autor:
Daniel Thomas Ginat, Victoria M. Villaflor, Mark W. Lingen, Nishant Agrawal, J.M. Melotek, Louis G. Portugal, Daniel J. Haraf, Sara Kochanny, Zhen Gooi, Theodore Karrison, Elizabeth A. Blair, Allison Dekker, Tanguy Y. Seiwert, Corey C. Foster, Ryan J. Brisson, E. E. Vokes
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 30(2)
Background Patients with HPV+ oropharyngeal squamous cell carcinoma were assigned to dose and volume de-escalated radiotherapy (RT) or chemoradiotherapy (CRT) based on response to induction chemotherapy in an effort to limit treatment-related toxicit
Autor:
N. Hannigan, Masha Kocherginsky, Michael T. Spiotto, Alexander Langerman, J.M. Melotek, J.A. de Souza, Victoria M. Villaflor, Louis G. Portugal, Daniel Thomas Ginat, Ezra E.W. Cohen, E. E. Vokes, Kerstin M. Stenson, Elizabeth A. Blair, Ryan J. Brisson, Tanguy Y. Seiwert, Daniel J. Haraf, Theodore Karrison
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 27(5)
BACKGROUND Efforts to reduce the late toxicity associated with chemoradiation (CRT) for locally advanced head and neck squamous cell cancer (LA-HNSCC) have focused on radiotherapy (RT) dose de-escalation. In this phase I/II protocol investigating the
Autor:
E. B. Lamont, D. Hayreh, K. E. Pickett, J. J. Dignam, M. A. List, K. M. Stenson, D. J. Haraf, B. E. Brockstein, S. A. Sellergren, E. E. Vokes
Publikováno v:
JNCI Journal of the National Cancer Institute. 95:1370-1375
Publikováno v:
British Journal of Cancer
Losoxantrone is a DNA intercalator that was developed with the potential to replace anthracyclines. The recommended single agent dose of losoxantrone is 50 mg m−2 every 3 weeks. We conducted a phase I study of losoxantrone and a fixed dose of cyclo
Publikováno v:
The Lancet. 350:1087-1091
Autor:
Shivani Nanda, David R. Gandara, Luis Paz-Ares, Javad Shahidi, Gerrit Grau, Mark A. Socinski, Nick Thatcher, Raffael Kurek, David R. Spigel, E. E. Vokes
Publikováno v:
Annals of Oncology. 27:vi435
Autor:
E. E. Vokes
Publikováno v:
The Oncologist. 6:25-27
Autor:
M. McHugh, L.C. Das, Tanguy Y. Seiwert, K. Heath, Victoria M. Villaflor, Ralph R. Weichselbaum, D Haraf, Jonathan D. Cheng, E. E. Vokes, Ryan J. Brisson
Publikováno v:
European Journal of Cancer. 51:S105
Autor:
E. E. Vokes, T. F. Pajak
Publikováno v:
Annals of Oncology. 9:471-473
Autor:
J. L. Villano, E. E. Vokes
Publikováno v:
Oncologic Therapies ISBN: 9783642628184
The Central Brain Tumor Registry of the United States estimates 11.3 cases per 100,000 person years for all primary benign and malignant brain tumors, with malignant brain tumors comprising half of the cases [1]. Similarly, the American Cancer Societ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97a7162ba68ea48b9c26f19f429bb66c
https://doi.org/10.1007/978-3-642-55780-4_42
https://doi.org/10.1007/978-3-642-55780-4_42